Thread by @JocelynnPearl

I wasn't at #JPM2023, but here are some of the articles I read and announcements that caught my eye from the meeting and #biotech this week!

.@BiotechCH (previously on Clubhouse) had a great one hour roundup; you can listen to the recording here:

https://twitter.com/BiotechCH/status/1613956801539571712?s=20&t=IOyLs4ymd_eOzZmmkV-XAQ

9 takeaways from @AndrewE_Dunn for @Insider
(cliff notes version by @bradloncar )

https://twitter.com/bradloncar/status/1611341479527546880?s=20&t=5mWxE-OFdJiRM1P1BZYfYw

.@afederation of @talusbio was excited by Genentech-Kronos and Genetech-Belharra deals; going all-in on small molecules for undruggables.

https://twitter.com/timmermanreport/status/1610718797505396736?s=20&t=IOyLs4ymd_eOzZmmkV-XAQ

Mike Holmes (former SGMO) shared that @TesseraTx has new NHP data for their gene writing platform

https://twitter.com/mcholmes_holmes/status/1613541813482303488?s=20&t=5mWxE-OFdJiRM1P1BZYfYw

.@HeraBiotech announces patient enrollment for endometriosis diagnostic study that will combine single cell analysis femtechworld.co.uk/news/biotech-s…

.@DayOneBio announced data from Pivotal Phase 2 FIREFLY-1 Trial Demonstrating Meaningful Responses with Tovorafenib (DAY101) in Pediatric Low-Grade Glioma ir.dayonebio.com/news-releases/…

Microbial Metagenomics co. @metagenomi closed a big $175M Series B

https://twitter.com/BanfieldJill/status/1489467741098557444?s=20&t=dQlqC6n3V0sO8xEnfBMFcA

Last but not least, @nathanvardi's book on the development of BTK inhibitors came out this past week; it's excellent! Features JP Morgan conf. and several prominent deals in the space. A great read.

https://twitter.com/JocelynnPearl/status/1614315614059003904?s=20&t=dQlqC6n3V0sO8xEnfBMFcA